Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm

References

• Tefferi A, Vardiman J W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008; 49: 388–397
   PubMed Web of Science ®Google Scholar
• Levine R L, Pardanani A, Tefferi A, Gillil D G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673–683
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic J P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434: 1144–1148
   PubMed Web of Science ®Google Scholar
• Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
   PubMed Web of Science ®Google Scholar
• Levine R L, Wadleigh M, Cools J, Ebert B L, Wernig G, Huntly B J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser A S, Teo S S, Tiedt R, Passweg J R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790
   PubMed Web of Science ®Google Scholar
• Jones A V, Kreil S, Zoi K, Waghom K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168
   PubMed Web of Science ®Google Scholar
• Campbell P J, Scott L M, Buck G, Wheatley K, East C, Marsden J T, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho T L, Schwager S M, Strand J S, Elliott M, Mesa R, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2(V617F) in polycythemia vera. Cancer 2006; 106: 631–635
   PubMed Web of Science ®Google Scholar
• Vannucchi A M, Antonioli E, Gugliemelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840–846
   PubMed Web of Science ®Google Scholar
• Shide K, Shimoda H K, Kumano T, Karube K, Kameda T, Kakenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22: 87–95
   PubMed Web of Science ®Google Scholar
• Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F, et al. The JAK2 617F>V mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110: 1013–1021
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki J H. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007; 21: 1097–1099
   PubMed Web of Science ®Google Scholar
• Scott L M, Tong W, Levine R L, Scott M A, Beer P A, Stratton M R, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468
   PubMed Web of Science ®Google Scholar
• Scott L M, Beer P A, Bench A J, Erber W N, Green A R. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007; 139: 511–512
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho T L, Finke C, Hanson C A, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960–1963
   PubMed Web of Science ®Google Scholar
• Williams D M, Kim A H, Rogers O, Spivak J L, Moliterno A R. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007; 35: 1641–1646
   PubMed Web of Science ®Google Scholar
• Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2(V617F)-negative myeloproliferative disorders. Blood 2008; 111: 1686–1689
   PubMed Web of Science ®Google Scholar
• Tiedt R, Hao-Shen H, Sobas M A, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931–3940
   PubMed Web of Science ®Google Scholar
• Wernig G, Mercher T, Okabe R, Levine R L, Lee B H, Gilliland D G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281
   PubMed Web of Science ®Google Scholar
• Bumm T G, Elsea C, Corbin A S, Loriaux M, Sherbenou D, Wood L, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66: 11156–11165
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, Matteo G, Porta D, Boveri E, et al. Relation between JAK2(V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–3682
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V, Spinelli O, Federica S, Delaini F, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007; 109: 2310–2313
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849
   PubMed Web of Science ®Google Scholar
• Wolanskyj A P, Lasho T L, Schwager S M, McClure R F, Wadleigh M, Lee S J, et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson R A, Lasho T, Finke C M, Gangat N, Wolanskyj A P, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–2284
   PubMed Web of Science ®Google Scholar